Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg lowers target price on MJ Gleeson

(Sharecast News) - Analysts at Berenberg lowered their target price on housebuilder MJ Gleeson from 642.0p to 500.0p on Thursday, stating the company was currently experiencing some "tough times". Following MJ Gleeson's unscheduled trading update on 3 June, Berenberg cut its earnings per share forecasts for MJ Gleeson by 20% on average over 2025-27.

In its trading update, MJ Gleeson indicated that its FY25 results would now come in below current market expectations, citing a combination of two factors.

Firstly, MJ Gleeson said that the margin performance in its Gleeson Homes division was lower than it had previously expected, as it continued to use selling incentives to drive demand, putting pressure on margins in the process.

Secondly, MJ Gleeson was expecting FY25 profits to benefit from the sale of a land holding, but the transaction did not proceed as it had initially expected.

"We make no change to our revenue forecasts, which reflects no changes to our volume or average selling price assumptions, with all earnings downgrades driven by the reduced margins," said the German bank, which maintained its 'buy' rating on the stock.

"We cut our EBIT, PBT and EPS forecasts by 18%, 20% and 20% respectively over 2025-27, on average. Our new PBT forecast for FY25 of GBP22m implies a decline of 13% yoy, before we expect growth of 13% in FY26. Our FY25 EBIT margin forecast now stands at 6.7%, down from c15% in 2021-22, illustrating the challenges the group has faced on this front."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.